Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

1. Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial (Abstract)

Perioperative Gabapentin in Pediatric Thoracic Surgery Patients-Randomized, Placebo-Controlled, Phase 4 Trial To determine whether the use of perioperative gabapentin reduces postoperative pain and anxiety, decreases ropivacaine consumption and side effects, and improves patient satisfaction.Randomized, placebo-controlled, phase 4 trial.Participants, care providers, investigators, data analysts.Department of Thoracic Surgery of the Institute of Tuberculosis and Lung Disease, Rabka Zdrój Branch (...) , Poland.Forty patients undergoing the Ravitch procedure.Patients aged nine to 17 years were randomized into a gabapentin (preoperative 15 mg/kg, treatment) or placebo group. Postoperative analgesia included gabapentin (7.5 mg/kg) or placebo two times per day for three days, epidural ropivacaine + fentanyl, paracetamol, nonsteroidal anti-inflammatory drugs, and metamizol as a "rescue drug." Pain, anxiety, analgesic consumption, side effects, and patient satisfaction were recorded.There was no statistically

2019 EvidenceUpdates

2. Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse (...) of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing pregabalin and gabapentin and observe patients for development of signs of abuse and dependence. Published 16 April 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: to reflect growing concern about abuse, both pregabalin and gabapentin are now classified as Class C controlled substances

2019 MHRA Drug Safety Update

3. Gabapentin and pregabalin: Are high doses justified?

Gabapentin and pregabalin: Are high doses justified? Gabapentin and pregabalin: Are high doses justified? January 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 117 A nalgesia once seemed a relatively straightfor- ward aspect of medicine. Recommendations in textbooks (...) and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, notion that more is likely to be better. 1 Recent experiments and systematic reviews show that drugs seldom outperform placebo significantly in chronic pain. Even old standards like acetaminophen and amitriptyline do not stand up well to careful scru- tiny of randomized placebo-controlled trials. 2,3 Recent evidence confirms that gabapentin and pregabalin

2019 Therapeutics Letter

4. A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis

A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

5. Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis

Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

6. A systematic review of the analgesic efficacy and safety of gabapentinoids (pregabalin and gabapentin) in the treatment of patients with neuropathic pain

A systematic review of the analgesic efficacy and safety of gabapentinoids (pregabalin and gabapentin) in the treatment of patients with neuropathic pain Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

7. Effects of a single dose of preoperative pregabalin and gabapentin for acute postoperative pain: a network meta-analysis of randomized controlled trials (Full text)

Effects of a single dose of preoperative pregabalin and gabapentin for acute postoperative pain: a network meta-analysis of randomized controlled trials Pregabalin (PGB) and gabapentin (GBP) are current and emerging drugs in the field of pre-emptive preoperative analgesia. However, the role of PGB or GBP in acute postoperative pain management still remains elusive.We conducted a comprehensive literature search of articles published by December 3, 2017. A total of 79 randomized controlled trials

2019 EvidenceUpdates PubMed abstract

8. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis

Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

9. Gabapentin add-on treatment for drug-resistant focal epilepsy. (Full text)

Gabapentin add-on treatment for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2013.Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCTs) of gabapentin, when used as an add-on treatment for drug-resistant (...) focal epilepsy.To evaluate the efficacy and tolerability of gabapentin when used as an add-on treatment for people with drug-resistant focal epilepsy.For the latest update, we searched the Cochrane Register of Studies (CRS Web, 20 March 2018), which includes the Cochrane Epilepsy Group's Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid, 1946 to 20 March 2018), ClinicalTrials.gov (20 March 2018) and the World Health Organization International

2018 Cochrane PubMed abstract

10. Gabapentin

Gabapentin Top results for gabapentin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gabapentin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

11. Gabapentin for Chronic Neuropathic Pain. (Abstract)

Gabapentin for Chronic Neuropathic Pain. Is gabapentin associated with pain relief in people with chronic neuropathic pain?Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo.

2018 JAMA

12. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial (Full text)

Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Guidelines recommend using gabapentin to decrease postoperative pain and opioid use, but significant variation exists in clinical practice.To determine the effect of perioperative gabapentin on remote postoperative time to pain resolution and opioid cessation.A randomized, double-blind, placebo-controlled trial of perioperative gabapentin was conducted (...) of participants with continued pain or opioid use at 6 months and 1 year.Of 1805 patients screened for enrollment, 1383 were excluded, including 926 who did not meet inclusion criteria and 273 who declined to participate. Overall, 8% of patients randomized were lost to follow-up. A total of 202 patients were randomized to active placebo and 208 patients were randomized to gabapentin in the intention-to-treat analysis (mean [SD] age, 56.7 [11.7] years; 256 (62.4%) women and 154 (37.6%) men). Baseline

2018 EvidenceUpdates PubMed abstract

13. The efficacy of gabapentin in the treatment of pain in patients experiencing idiopathic trigeminal neuralgia: a systematic review of randomised controlled trials

The efficacy of gabapentin in the treatment of pain in patients experiencing idiopathic trigeminal neuralgia: a systematic review of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

14. A systematic review of the efficacy and safety of gabapentin and pregabalin in the treatment of patients with sciatica

A systematic review of the efficacy and safety of gabapentin and pregabalin in the treatment of patients with sciatica Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

15. The role of gabapentin as a premedication in shoulder surgery

The role of gabapentin as a premedication in shoulder surgery Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

16. Perioperative gabapentin and post cesarean pain control: a systematic review and meta-analysis of randomized controlled trials

Perioperative gabapentin and post cesarean pain control: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

17. Does gabapentin for acute or subacute pain associated with herpes zoster prevent postherpetic neuralgia? A systematic review and meta-analysis of randomized controlled trials

Does gabapentin for acute or subacute pain associated with herpes zoster prevent postherpetic neuralgia? A systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2018 PROSPERO

18. Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Last updated: March 12, 2018 Project Number: RC0970-000 Product Line: Research Type: Drug Report Type: Summary (...) with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for adults with neuropathic pain? Key Message The findings from four systematic reviews and one RCT for gabapentin (GBP) compared to placebo or active comparators is limited by quantity and quality of evidence for studies on neuropathic pain associated with conditions including chronic lower back pain, fibromyalgia, mixed neuropathic pain, and nerve injury pain. While some studies reported little

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Gabapentin (Neurontin): risk of severe respiratory depression

Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin (Neurontin): risk of severe respiratory depression - GOV.UK GOV.UK uses cookies to make the site simpler. Search Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin has been associated with a rare risk of severe respiratory depression even without concomitant opioid medicines. Patients with compromised respiratory function, respiratory or neurological disease, renal impairment, concomitant use (...) of central nervous system (CNS) depressants, and elderly people might be at higher risk of experiencing severe respiratory depression. Dose adjustments might be necessary in these patients. Published 26 October 2017 From: Therapeutic area: , Contents Advice for healthcare professionals: be aware of the risk of CNS depression, including severe respiratory depression, with gabapentin consider whether dose adjustments might be necessary in patients at higher risk of respiratory depression, including elderly

2017 MHRA Drug Safety Update

20. Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial (Full text)

Comparison of the effect of topiramate versus gabapentin on neuropathic pain in patients with polyneuropathy: A randomized clinical trial Neuropathic pain is one of the most common complaints of neurologic clinics. Neuropathic pain is common and important and has inappropriate complications, and despite their importance, there is no effective treatment for them.Because of the importance of neuropathic pain and safe and effective treatment, in this study, we determined the effect of topiramate (...) versus gabapentin in patients with neuropathic pain.In this randomized clinical trial, 30 patients with pain attributed to neuropathy who had at least one month of neuropathic pain in one area, were randomized to receive either gabapentin, titrated from 300 mg/day to a maximum of 900 mg/day or topiramate, titrated from 50 mg/day to a maximum of 100 mg/day after a 4-week period in the neurology clinic of Imam Khomeini Hospital of Urmia city, Iran in 2015. Complication, drug tolerance rate and pain

2017 Electronic physician Controlled trial quality: uncertain PubMed abstract